Part of me hopes you're correct about AMBS going with one partner for MANF. From an investment research standpoint, it would be much easier to identify the small number of players that have the significant scientific, financial, regulatory, sales and marketing resources to develop MANF for all the disease indications it may be able to address.

There just aren't many large pharma and biotech companies that can be experts in everything from cardiovascular and neurodegenerative diseases to diabetes and orphan diseases such as Wolfram syndrome.